| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
|
Lancet Oncol
|
2009
|
3.91
|
|
2
|
Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius.
|
Blood
|
2011
|
2.87
|
|
3
|
Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells.
|
Transfusion
|
2007
|
2.20
|
|
4
|
Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.
|
Blood
|
2013
|
2.01
|
|
5
|
Humanized large-scale expanded endothelial colony-forming cells function in vitro and in vivo.
|
Blood
|
2009
|
2.00
|
|
6
|
Blood monocytes mimic endothelial progenitor cells.
|
Stem Cells
|
2005
|
1.79
|
|
7
|
Rapid large-scale expansion of functional mesenchymal stem cells from unmanipulated bone marrow without animal serum.
|
Tissue Eng Part C Methods
|
2008
|
1.73
|
|
8
|
Immune cells mimic the morphology of endothelial progenitor colonies in vitro.
|
Stem Cells
|
2007
|
1.66
|
|
9
|
Humanized system to propagate cord blood-derived multipotent mesenchymal stromal cells for clinical application.
|
Regen Med
|
2007
|
1.57
|
|
10
|
(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial.
|
J Clin Oncol
|
2012
|
1.50
|
|
11
|
Long-term results of dose density therapy in patients with aggressive lymphoma.
|
Ann Hematol
|
2004
|
1.40
|
|
12
|
Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group.
|
J Hematol Oncol
|
2013
|
1.34
|
|
13
|
Common alterations in gene expression and increased proliferation in recurrent acute myeloid leukemia.
|
Oncogene
|
2004
|
1.26
|
|
14
|
Two steps to functional mesenchymal stromal cells for clinical application.
|
Transfusion
|
2007
|
1.23
|
|
15
|
Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group.
|
Ann Hematol
|
2014
|
1.22
|
|
16
|
The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling.
|
Blood
|
2007
|
1.18
|
|
17
|
Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia.
|
Cancer Res
|
2006
|
1.08
|
|
18
|
Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia.
|
Haematologica
|
2011
|
1.03
|
|
19
|
Phenotypic characterization and preclinical production of human lineage-negative cells for regenerative stem cell therapy.
|
Transfusion
|
2005
|
1.02
|
|
20
|
Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study.
|
J Clin Oncol
|
2002
|
1.02
|
|
21
|
Defective DNA-mismatch repair: a potential mediator of leukemogenic susceptibility in therapy-related myelodysplasia and leukemia.
|
Genes Chromosomes Cancer
|
2002
|
1.01
|
|
22
|
Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis.
|
Blood
|
2002
|
1.00
|
|
23
|
MALT lymphoma and extranodal diffuse large B-cell lymphoma are targeted by aberrant somatic hypermutation.
|
Blood
|
2006
|
0.99
|
|
24
|
Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial.
|
Biol Blood Marrow Transplant
|
2012
|
0.97
|
|
25
|
Restoration of erythropoiesis by rituximab in an adult patient with primary acquired pure red cell aplasia refractory to conventional treatment.
|
Br J Haematol
|
2002
|
0.97
|
|
26
|
European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies.
|
J Antimicrob Chemother
|
2012
|
0.93
|
|
27
|
Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie.
|
Haematologica
|
2012
|
0.92
|
|
28
|
Impact of galactomannan testing on the prevalence of invasive aspergillosis in patients with hematological malignancies.
|
Med Mycol
|
2011
|
0.91
|
|
29
|
Myeloid sarcoma presenting in muscle-tissue of the lower limb: unusual origin of a compartment-syndrome.
|
Am J Clin Oncol
|
2007
|
0.90
|
|
30
|
Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of the European group for Blood and Marrow Transplantation.
|
Br J Haematol
|
2014
|
0.86
|
|
31
|
Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop.
|
Eur J Cancer
|
2008
|
0.86
|
|
32
|
A functional single-nucleotide polymorphism of the G-CSF receptor gene predisposes individuals to high-risk myelodysplastic syndrome.
|
Blood
|
2005
|
0.85
|
|
33
|
Dendritic cell deficiency in early B cell chronic lymphocytic leukemia.
|
Haematologica
|
2004
|
0.83
|
|
34
|
Evaluation of mutations in the isocitrate dehydrogenase genes in therapy-related and secondary acute myeloid leukaemia identifies a patient with clonal evolution to IDH2 R172K homozygosity due to uniparental disomy.
|
Br J Haematol
|
2011
|
0.83
|
|
35
|
Roscovitine in B-chronic lymphocytic leukemia cells: high apoptosis-inducing efficacy and synergism with alemtuzumab independent of the patients' pretreatment status.
|
Haematologica
|
2007
|
0.82
|
|
36
|
Histiocytic sarcoma - targeted therapy: novel therapeutic options? A series of 4 cases.
|
Onkologie
|
2012
|
0.82
|
|
37
|
Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
|
Ann Hematol
|
2014
|
0.82
|
|
38
|
Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation.
|
Clin Ther
|
2009
|
0.81
|
|
39
|
A case of generalized MALT lymphoma with IgM paraproteinemia and peripheral blood involvement.
|
Ann Hematol
|
2009
|
0.81
|
|
40
|
Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study.
|
Eur J Haematol
|
2002
|
0.80
|
|
41
|
Factors affecting long-term outcome after allogeneic haematopoietic stem cell transplantation for acute myelogenous leukaemia: a retrospective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry.
|
Br J Haematol
|
2002
|
0.80
|
|
42
|
Chlamydia psittaci in MALT lymphomas of ocular adnexals: the Austrian experience.
|
Leuk Res
|
2007
|
0.80
|
|
43
|
Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform.
|
Wien Klin Wochenschr
|
2008
|
0.80
|
|
44
|
Occurrence of a myelodysplastic syndrome (MDS) during first-line 2-chloro-deoxyadenosine (2-CDA) treatment of a low-grade gastrointestinal MALT lymphoma. Case report and review of the literature.
|
Haematologica
|
2004
|
0.79
|
|
45
|
Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial.
|
Ann Hematol
|
2014
|
0.78
|
|
46
|
CHOP chemotherapy followed by Rituximab consolidation as first line treatment in patients with follicular lymphoma. Long-term follow-up of a phase 2 trial.
|
Eur J Haematol
|
2007
|
0.77
|
|
47
|
Radioimmunotherapy confers long-term survival to lymphoma patients with acceptable toxicity: registry analysis by the International Radioimmunotherapy Network.
|
J Nucl Med
|
2011
|
0.76
|
|
48
|
Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
|
Transfusion
|
2010
|
0.76
|
|
49
|
Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions.
|
Crit Rev Oncol Hematol
|
2011
|
0.76
|
|
50
|
Questionable benefit of melatonin for antioxidant pharmacologic therapy.
|
J Clin Oncol
|
2002
|
0.75
|
|
51
|
Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR).
|
Ann Hematol
|
2005
|
0.75
|
|
52
|
Safety and tolerability of intrathecal liposomal cytarabine as central nervous system prophylaxis in patients with acute lymphoblastic leukemia.
|
Leuk Lymphoma
|
2013
|
0.75
|
|
53
|
Fatal sepsis after thalidomide/dexamethasone treatment in two patients with multiple myeloma.
|
Haematologica
|
2003
|
0.75
|
|
54
|
AntiCD20 monoclonal antibody-based radioimmunotherapy of relapsed chemoresistant aggressive post-transplantation B-lymphoproliferative disorder in heart-transplant recipient.
|
Lancet Oncol
|
2005
|
0.75
|
|
55
|
Spontaneous tumor lysis syndrome presenting as acute renal failure in an adult with de novo aleukemic T-ALL: value of renal biopsy?
|
J Clin Oncol
|
2011
|
0.75
|
|
56
|
Symptomatic Epstein-Barr virus reactivation in a patient with acute myeloid leukaemia and treatment with the monoclonal anti-CD20 antibody rituximab.
|
Eur J Haematol
|
2002
|
0.75
|
|
57
|
[Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)].
|
Wien Klin Wochenschr
|
2012
|
0.75
|
|
58
|
High-dose hydroxyurea plus G-CSF mobilize BCR-ABL-negative progenitor cells (CFC, LTC-IC) into the blood of newly diagnosed CML patients at any time of hematopoietic regeneration.
|
J Hematother Stem Cell Res
|
2002
|
0.75
|
|
59
|
[The use of erythropoiesis-stimulating proteins in anemic patients with malignant diseases].
|
Wien Klin Wochenschr
|
2008
|
0.75
|
|
60
|
Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemia.
|
Haematologica
|
2003
|
0.75
|
|
61
|
Upfront radioimmunotherapy represents an effective and safe therapeutic option in cutaneous B-cell non-Hodgkin lymphoma.
|
Ann Hematol
|
2011
|
0.75
|
|
62
|
Pyoderma gangrenosum heralding acute leukemia for months: diagnostic hint written on the skin.
|
J Clin Oncol
|
2011
|
0.75
|
|
63
|
Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma.
|
Br J Haematol
|
2005
|
0.75
|